drugset
Drugs / BTZ-043
last change 16 days ago re-read 9 days ago

BTZ-043

also known as BTZ-10526043 · Bzt043

Small molecule

Developed for
pulmonary tuberculosis · tuberculosis
Investigated by
Michael Hoelscher · Radboud University Medical Center · GlaxoSmithKline · University College, London · University of California, San Francisco · German Center for Infection Research
+31 more · German Federal Ministry of Education and Research · TASK Applied Science · Click-TB Consortium · Critical Path Institute · European Lung Foundation · European Respiratory Society · European and Developing Countries Clinical Trials Partnership (EDCTP) · Find · Hans Knöll Institute (HKI) · Helmholtz Zentrum München · Instituto de Saude Publica da Universidade do Porto · Janssen, LP · KNCV Tuberculosis Foundation · Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute · LigaChem Biosciences, Inc. · London School of Hygiene and Tropical Medicine · Ludwig-Maximilians - University of Munich · Lygature · Otsuka Pharmaceutical Development & Commercialization, Inc. · Research Center Borstel · Research Institute for Development · TB Alliance · Tuberculosis Network European Trialsgroup · University of Cambridge · University of Hamburg-Eppendorf · University of Liverpool · University of Milano · University of Oxford · University of St Andrews · Uppsala University · Vita-Salute San Raffaele University

Trials 8

today NCT07773610 · Ph 2 NCT06114628 · Ph 2 NCT05926466 · Ph 2 NCT05807399 · Ph 2 NCT05382312 · Ph 2 NCT04874948 · Ph 1 NCT04044001 · Ph 1/2 NCT03590600 · Ph 1
2019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04874948 Oct 2021 lung disorder, pulmonary tuberculosis, respiratory tract infectious disorder Michael Hoelscher Completed No outcome recorded
Phase 1 NCT03590600 Jun → Aug 2018 lung disorder, pulmonary tuberculosis Michael Hoelscher Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04044001 Nov 2019 → Mar 2022 pulmonary tuberculosis Michael Hoelscher Completed No outcome recorded
Phase 25 trials
Phase 2 NCT07773610 Sep 2026 → Dec 2027 expected pulmonary tuberculosis TASK Applied Science Not yet recruiting No outcome recorded
Phase 2 NCT06114628 Jan 2024 → Feb 2027 expected pulmonary tuberculosis University College, London Recruiting No outcome recorded
Phase 2 NCT05926466 Sep 2023 → Dec 2024 pulmonary tuberculosis Michael Hoelscher Completed No outcome recorded
Phase 2 NCT05807399 Apr 2023 → Oct 2027 expected pulmonary tuberculosis Michael Hoelscher Recruiting No outcome recorded
Phase 2 NCT05382312 Jul 2022 → May 2025 tuberculosis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as BTZ-043 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05382312 ↗
7

NCT07773610 ↗

NCT04044001 ↗

NCT04874948 ↗

NCT05807399 ↗

NCT05926466 ↗

NCT03590600 ↗

NCT06114628 ↗
Known as BTZ-10526043 ChEMBL registry synonym — accepted as the source's own label CHEMBL1822872 ↗
Known as Bzt043 ChEMBL registry synonym — accepted as the source's own label CHEMBL1822872 ↗
Action Inhibit “BTZ-043, a first-in-class DprE1 inhibitor with strong bactericidal activity in murine models.” PMID 39793592 ↗ Jan 2025
Modality Small molecule “BTZ-043 belongs to the chemical class of benzothiazinones” NCT05926466 ↗
Route Oral “N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose” NCT03590600 ↗